Review
Nature Reviews Drug Discovery 5, 333-342 (April 2006) | doi:10.1038/nrd2007
Lipid phosphatases as drug discovery targets for type 2 diabetes
Dan F. Lazar1,1 & Alan R. Saltiel2 About the authors
Abstract
The soaring incidence of type 2 diabetes has created pressure for new pharmaceutical strategies to treat this devastating disease. With much of the focus on overcoming insulin resistance, investigation has focused on finding ways to restore activation of the phosphatidylinositol 3'-kinase pathway, which is diminished in many patients with type 2 diabetes. Here we review the evidence that lipid phosphatases, specifically PTEN and SHIP2, attenuate this important insulin signalling pathway. Both in vivo and in vitro studies indicate their role in regulating whole-body energy metabolism, and possibly weight gain as well. The promise and challenges presented by this new class of drug discovery targets will also be discussed.
- View At a Glance
Author affiliations
- Eli Lilly and Co., Endocrine Division, Lilly Research Laboratories, Indianapolis, Indianapolis 46285, USA.
- Life Sciences Institute, 210 Washtenaw Avenue 3rd Floor, Ann Arbor, Michigan 48109-2216, USA.
Correspondence to: Email: lazar_dan_f@lilly.com
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
Staying in SHIP shapeNature Medicine News and Views (01 Feb 2005)
Turning up the heat in the fat cellNature Medicine News and Views (01 Nov 2004)
RESEARCH
A CD14-independent LPS receptor clusterNature Immunology Article (01 Apr 2001)
Absence of the lipid phosphatase SHIP2 confers resistance to dietary obesityNature Medicine Article (01 Feb 2005)
See all 30 matches for Research
